First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Abstract Text:

Ofatumumab is a unique monoclonal antibody that targets a distinct small loop epitope on the CD20 molecule. Preclinical data show that ofatumumab is active against B-cell lymphoma/chronic lymphocytic leukemia cells with low CD20-antigen density and high expression of complement inhibitory molecules. In a phase 1/2 trial evaluating safety and efficacy of ofatumumab in relapsed or refractory follicular non-Hodgkin lymphoma (FL) grade 1 or 2, 4 dose groups of 10 patients received 4 weekly infusions of 300, 500, 700, or 1000 mg. Patients had a median of 2 prior FL therapies and 13% had elevated lactate dehydrogenase. No safety concerns or maximum tolerated dose was identified. A total of 274 adverse events were reported; 190 were judged related to ofatumumab, most occurring on the first infusion day with Common Terminology Criteria grade 1 or 2. Eight related events were grade 3. Treatment caused immediate and profound B-cell depletion, and 65% of patients reverted to negative BCL2 status. Clinical response rates ranged from 20% to 63%. Median time to progression for all patients/responders was 8.8/32.6 months, and median duration of response was 29.9 months at a median/maximum follow-up of 9.2/38.6 months. Ofatumumab is currently being evaluated in patients with rituximab-refractory FL. This trial was registered at www.clinicaltrials.gov as #NCT00092274.

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Blood

VOLUME: 111

Page Numbers: 5486-95

Journal Abbreviation: Blood

ISSN: 1528-0020

DAY: 4

MONTH: 04

YEAR: 2008

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

AFFILIATION: University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands. a.hagenbeek@umcutrecht.nl

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Related Publications

• A Common {beta}-Sheet Architecture Underlies in Vitro and in Vivo {beta}2-Microglobulin Amyloid Fibrils.
• A novel technique for wound irrigation.
• Anterior midline or medial parapatellar incision for arthroplasty of the knee. A comparative study.
• Biological detergents.
• Carcinoma of the breast; a clinical lecture.
• Cognitive abilities as predictors of safety to drive in people with multiple sclerosis.
• Cooperative sentinel calling? Foragers gain increased biomass intake.
• Depressive patients are more impulsive and inconsistent in intertemporal choice behavior for monetary gain and loss than healthy subjects - An analysis based on Tsallis' statistics.
• Effect of surfactant on surface hardness of dental stone and investment casts produced from polyvinyl siloxane duplicating materials.
• Embolization of a dural sinus fistula by direct puncture of the occipital arteries.
• Familial muscular ventricular septal defects and aneurysms of the muscular interventricular septum.
• Fibril Growth Kinetics Reveal a Region of beta(2)-microglobulin Important for Nucleation and Elongation of Aggregation.
• First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
• Folding versus aggregation: polypeptide conformations on competing pathways.
• High-altitude oedema presenting as coma.
• INVESTMENT ADVICE-FROM WHERE?
• Ink caps and mushrooms.
• Long-term dimensional stability and reproduction of surface detail of four polyvinyl siloxane duplicating materials.
• Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.
• Perinatal mortality and one-year infant morbidity.
• Serologic survey of Leptospira pomona infection in Wyoming cattle.
• Sex differences in the relationship between cortisol levels and the Empathy and Systemizing Quotients in humans.
• Source of contamination in haemodialysis equipment.
• Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly.
• THE STOCK EXCHANGE--SHORTCOMINGS.
• The extensively restored posteriortooth has a high incidence of tooth fracture.
• The ranibizumab saga of drug profiteering.
• The relation between cardiorespiratory fitness and coronary artery calcification progression in women: 713: may 31 2:30 PM 2:45 PM.
• Type of threat influences postconflict allopreening in a social bird.
• Unraveling the molecular basis of subunit specificity in P pilus assembly by mass spectrometry.